Revista de Farmacologia Clínica e Experimental

Abstrato

Accessibility, Cost Effective Immunotherapy in Serbia for patients with metastatic colorectal cancer

Kovacevic Aleksandra

Colorectal cancer has been a health burden for many years. Although it's considered to be a disease of the developed world, the incidence rate of CRC has been on the increase in developing countries also (Favoriti et al., 2016; Douaiher et al., 2017). consistent with the planet Health Organization GLOBOCAN database (Bray et al., 2018), is that the third most ordinarily diagnosed cancer and therefore the fourth main explanation for cancer death within the world, accounting for 881,000 deaths in 2018. Colorectal cancer also causes substantial morbidity and mortality in Serbia. consistent with an equivalent database, the amount of latest cases of in 2018 was 6,049 (12.6% of any sort of cancer), while the amount of the deaths caused by was 3,187 (2.9% of all cancer-related deaths) (The Global Cancer Observatory, 2018). The Serbian health system is facing an additional challenge due to a steep rise in the number of people diagnosed with CRC. From 1997 to 2007, the incidence of CRC increased by 24.6% (Knezevic, 2009). Since this trend will, without doubt, stress the National Health Insurance Fund (NHIF) of Serbia, the objectives of this study were to identify different types of medical services provided to CRC patients and therefore the associated expenditures so as to estimate the entire medical cost at the national level between 2104 and 2017. This information is expected to assist healthcare decision planners and policymakers on how to allocate resources optimally.